Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

A method for treating or preventing a viral infection in a subject, said method comprising administering to said subject a pharmaceutically effective amount of a compound having the formula:

• or pharmaceutically acceptable salts thereof,
• wherein L is NR2, O, S, C(═O)N, CR2R3CR2R3, CR2R3NR2, CR4═CR4, CR2R3O, CR2R3S, NR2CR2R3, NR2C(═O), NS(O)t , OCR2R3, SCR2R3;
• V is (CR2R3)u, C(═O)CR2R3, CR2R3O, CR2R3OCR2R3, CR4═CR4, C(=NR2), or C(═O);
• Q is NR2, O, S(O)t, or a bond;
• t=0, 1, 2;
• u=0-3;
• wherein a dashed line indicates the presence or absence of a bond;
• R1 is Ra, OR2, or NR2R3;
• each Ra is independently H, optionally substituted hydrocarbyl, optionally substituted aryl, optionally substituted heteroaryl;
• R2 and R3 are each independently Ra, C(═O)Ra, SO2Ra, or R2 and R3 form an optionally substituted carbocyclic, heterocarbocyclic, aryl, or heteroaryl ring;
• each R4 is independently R2, ORa, C(═O)Ra, C(═O)NR2R3, NR2R3, NRb(═O)Ra, SRa, SORa, SO2Ra, SO2NHRa, SO2NR2R3, NCORa, halogen, trihalomethyl, CN, S═O, nitro, or two R4 groups form an optionally substituted carbocyclic, heterocarbocyclic, aryl, or heteroaryl ring;
• W and X are each independently N, NRa, NRS, O, S, CR2R4 or CR4;
• R5 is Ra, C(═O)Ra, SO2Ra, or is not present;
• and
• Y1, Y2, Y3 and Y4 are each independently CR4 or N.